Search Follow us

EdisonTV

NeuroVive Pharmaceutical

EdisonTV | Pharmaceutical & healthcare | 24/04/2018

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.

Read the report

Executive interview – Verona Pharma

Executive interview – Verona Pharma

Verona Pharma’s chairman, Dr David Ebsworth, provides an overview of the group’s core technology and applications, corporate strategy and development plans for its lead product, RPL554. He also outlines expected near-term news flow and the regulatory strategy.
Watch »

10/12/2018 | Verona Pharma

Executive interview – Paion

Executive interview – Paion

CEO Dr Wolfgang Söhngen provides an overview of Paion’s core technology, Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic. He also discusses the group’s strategy including partnership deals with Cosmo and Mundipharma and the path to market for Paion’s products.
Watch »

10/12/2018 | Paion

Executive interview – Ergomed

Executive interview – Ergomed

CEO Stephen Stamp discusses trends in the pharmacovigilance and clinical research markets as well as the current structure and focus of the business following the acquisition of PSR.
Watch »

10/12/2018 | Ergomed

Executive interview – InflaRx

Executive interview – InflaRx

CEO and founder, Niels Riedemann, discusses InflaRx’s core technology including its lead product, IFX-1. He also highlights the advantages of the company’s acute and chronic inflammation products versus the current standard of care and the competition. Finally, he provides an update on InflaRx’s expected near-term news flow.
Watch »

10/12/2018 | InflaRx

Executive interview – PBKM

Executive interview – PBKM

Jakub Baran, CEO of PBKM, a Polish stem cell bank, discusses the group’s corporate strategy including the acquisitions made to increase its geographical reach. He also provides an overview of both the services and preclinical sides of the business.
Watch »

10/12/2018 | Expedeon

Executive Interview - Expedeon

Executive Interview - Expedeon

Dr Heikki Lanckriet, CEO of Expedeon, outlines the group’s Grow, Buy and Build strategy including recent acquisitions and the group’s acquisition criteria. He also discusses Expedeon’s financial turnaround and the impact it has made on financing recent acquisitions, before outlining the group’s five core technologies.
Watch »

06/12/2018 | Expedeon

Executive Interview - Heidelberg Pharma

Executive Interview - Heidelberg Pharma

Dr Jan Schmidt-Brand, CEO and CFO of Heidelberg discusses the group’s core technology and applications. In particular, he focuses on Heidelberg's lead product HDP-101’s route to market and its advantages over the current standard of care and competitors such as CAR-T and ADCs.
Watch »

06/12/2018 | Heidelberg Pharma

Executive interview – Oryzon

Executive interview – Oryzon

Oryzon Genomics is a biotech company focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and small-cell lung cancer; Vafidemstat, its CNS product, is in Phase IIa trials in multiple sclerosis, Alzheimer’s disease and aggression. Newer asset ORY-3001 is being developed for certain orphan indications. In this video, the company’s Chief Executive Officer, Carlos Buesa, and Chief Medical Officer Roger Bullock explain the recent R&D progress and expected newsflow.
Watch »

21/11/2018 | Oryzon Genomics

Executive Interview – True Leaf

Executive Interview – True Leaf

True Leaf is a plant-focused wellness brand for people and their pets. Founded in 2013, True Leaf has two main operating divisions: True Leaf Medicine and True Leaf Pet. The company’s goal is to provide federally approved medicinal cannabis products that will be sold across Canada and the United States.
Watch »

19/11/2018 | True Leaf

VolitionRx third quarter 2018 earnings review

VolitionRx third quarter 2018 earnings review

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Watch »

08/11/2018 | VolitionRx

Bitesize briefing - Nuevolution

Bitesize briefing - Nuevolution

Nuevolution is a Copenhagen-based biopharmaceutical company with a patent-protected drug discovery platform (Chemetics) that enables the selection of drugs for an array of tough-to-drug disease targets. In this video, healthcare analyst Dr Daniel Wilkinson presents an overview of Nuevolution, covering its technology, financial position, partnerships and the wider competitive landscape. Additionally he details Edison’s approach to valuing the company.
Watch »

25/09/2018 | Nuevolution

Executive interview – VolitionRx

Executive interview – VolitionRx

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Watch »

20/08/2018 | VolitionRx

Executive interview – ASIT Biotech

Executive interview – ASIT Biotech

ASIT Biotech is a Belgian biotechnology company focused on late-stage clinical development of allergy immunotherapies (AITs). Its first product in Phase III is a grass pollen AIT with the advantages of a very short administration. ASIT’s AITs require only four treatment visits in 3 weeks to the allergist prior to the pollen season rather than visits for most of the year which are needed with other subcutaneous AITs, or over many years for sublingual AITs. CEO, Thierry Legon, discusses the advantages of ASIT’s technology, its strong patent position and the timing for its next Phase III study, and the potential for ASIT’s technology platform to generate AITs in other allergy indications.
Watch »

16/07/2018 | ASIT Biotech

Executive interview - Kane Biotech

Executive interview - Kane Biotech

Kane Biotech (TSX-V: KNE, OTCQB: KNBIF) is taking a unique approach to addressing human and animal health by developing technology to break up biofilms, the glue-like substance secreted by microorganisms that prevent their removal. Biofilms are implicated in a range of health concerns from periodontal disease, medical device-associated infections, hospital-acquired infections and food safety.
Watch »

16/05/2018 | Kane Biotech

Bitesize briefing - NeuroVive Pharmaceutical

Bitesize briefing - NeuroVive Pharmaceutical

Mitochondrial disease is an umbrella term that includes a diverse set of conditions where the function of the mitochondria is failing. The diversity of the clinical presentation, low incidence rates and high unmet need make this an interesting area for specialist orphan drug developers. Here, healthcare analyst Dr Jonas Peciulis presents an overview of mitochondrial medicine, the competitive landscape in drug development and discusses one of the companies covered by Edison, specialising in the field, NeuroVive Pharmaceutical.
Watch »

24/04/2018 | NeuroVive Pharmaceutical

VolitionRx: Results from asymptomatic CRC trial reported

VolitionRx: Results from asymptomatic CRC trial reported

VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study demonstrated 80% sensitivity against stage 1 CRC and 66% against high-risk adenomas (at 78% specificity). The company has stated that it is moving on to the 4,300-sample study to determine the final test panel for European launch (results in Q218). This will be followed by a 12,000+ sample blinded study which is expected to complete in H218.
Watch »

20/03/2018 | VolitionRx

VolitionRX reports their Full Year 2017 Earnings

VolitionRX reports their Full Year 2017 Earnings

VolitionRx Limited (VNRX:US), a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced its Full Year 2017 earnings and will discuss this news as well as a business update on a conference call this morning. The company this week also announced interim results from a 680-Subject Clinical Trial in Colorectal Cancer.
Watch »

02/03/2018 | VolitionRx

Executive interview - Curetis NV

Executive interview - Curetis NV

Founded in 2007, Curetis is a developer of next-level molecular diagnostic solutions. Curetis focuses on the research, development and commercialisation of dependable, timely and cost-effective products that can be used to diagnose severe infectious diseases. The diagnostic achievements and progress the company is making enable rapid, multi-parameter pathogen and antibiotic resistance marker detection. It has designed the Unyvero platform, a fast, comprehensive diagnostics system that analyses severe infectious diseases in hospitalized patients. Using an array of cartridges, infectious diseases such as pneumonia or implant/tissue infections can be easily and rapidly diagnosed. While the current standard of diagnosis can take days or even weeks, Curetis can typically diagnose in four to five hours, either in a hospital laboratory or directly at the "point of need" in the intensive care unit.
Watch »

02/03/2018 | Curetis NV

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer

VolitionRx Limited, a multi-national life sciences company developing simple, easy to use blood-based cancer tests, today announced interim results from a 680-subject clinical trial in colorectal cancer. The study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer using Volition’s Nu.Q™ blood test.
Watch »

26/02/2018 | VolitionRx

Executive Interview - NeuroVive Pharmaceutical (Part 2)

Executive Interview - NeuroVive Pharmaceutical (Part 2)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.
Watch »

17/01/2018 |

Executive Interview - NeuroVive Pharmaceutical (Part 3)

Executive Interview - NeuroVive Pharmaceutical (Part 3)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.
Watch »

15/12/2017 |